These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38332154)

  • 1. Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant.
    Tamura T; Irie T; Deguchi S; Yajima H; Tsuda M; Nasser H; Mizuma K; Plianchaisuk A; Suzuki S; Uriu K; Begum MM; Shimizu R; Jonathan M; Suzuki R; Kondo T; Ito H; Kamiyama A; Yoshimatsu K; Shofa M; Hashimoto R; Anraku Y; Kimura KT; Kita S; Sasaki J; Sasaki-Tabata K; Maenaka K; Nao N; Wang L; Oda Y; ; Ikeda T; Saito A; Matsuno K; Ito J; Tanaka S; Sato K; Hashiguchi T; Takayama K; Fukuhara T
    Nat Commun; 2024 Feb; 15(1):1176. PubMed ID: 38332154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants.
    Tamura T; Ito J; Uriu K; Zahradnik J; Kida I; Anraku Y; Nasser H; Shofa M; Oda Y; Lytras S; Nao N; Itakura Y; Deguchi S; Suzuki R; Wang L; Begum MM; Kita S; Yajima H; Sasaki J; Sasaki-Tabata K; Shimizu R; Tsuda M; Kosugi Y; Fujita S; Pan L; Sauter D; Yoshimatsu K; Suzuki S; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Yamamoto Y; Nagamoto T; Schreiber G; Maenaka K; ; Hashiguchi T; Ikeda T; Fukuhara T; Saito A; Tanaka S; Matsuno K; Takayama K; Sato K
    Nat Commun; 2023 May; 14(1):2800. PubMed ID: 37193706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balancing Functional Tradeoffs between Protein Stability and ACE2 Binding in the SARS-CoV-2 Omicron BA.2, BA.2.75 and XBB Lineages: Dynamics-Based Network Models Reveal Epistatic Effects Modulating Compensatory Dynamic and Energetic Changes.
    Verkhivker G; Alshahrani M; Gupta G
    Viruses; 2023 May; 15(5):. PubMed ID: 37243229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Analysis of Conformational Dynamics and Systematic Characterization of Cryptic Pockets in the SARS-CoV-2 Omicron BA.2, BA.2.75 and XBB.1 Spike Complexes with the ACE2 Host Receptor: Confluence of Binding and Structural Plasticity in Mediating Networks of Conserved Allosteric Sites.
    Alshahrani M; Gupta G; Xiao S; Tao P; Verkhivker G
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural evolution of SARS-CoV-2 omicron in human receptor recognition.
    Zhang W; Shi K; Geng Q; Herbst M; Wang M; Huang L; Bu F; Liu B; Aihara H; Li F
    J Virol; 2023 Aug; 97(8):e0082223. PubMed ID: 37578233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Surveillance Reveals the Rapid Expansion of the XBB Lineage among Circulating SARS-CoV-2 Omicron Lineages in Southeastern Wisconsin, USA.
    Ramaiah A; Khubbar M; Akinyemi K; Bauer A; Carranza F; Weiner J; Bhattacharyya S; Payne D; Balakrishnan N
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological and Mitochondriopathogical Characteristics of the SARS-CoV-2 Omicron XBB.1.16 Spike.
    Fang L; Kang X; Hong Q; Xue C; Pan L; Chen J; Tang C; Sun L; Xu X; Yuan J; Du Y; Xu A
    ACS Appl Mater Interfaces; 2024 Jun; 16(23):29716-29727. PubMed ID: 38814480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.
    Parums DV
    Med Sci Monit; 2023 Feb; 29():e939580. PubMed ID: 36722047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
    Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X
    Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of intrinsic and effective fitness changes caused by temporarily fixed mutations in the SARS-CoV-2 spike E484 epitope and identification of an epistatic precondition for the evolution of E484A in variant Omicron.
    Schröder S; Richter A; Veith T; Emanuel J; Gudermann L; Friedmann K; Jeworowski LM; Mühlemann B; Jones TC; Müller MA; Corman VM; Drosten C
    Virol J; 2023 Nov; 20(1):257. PubMed ID: 37940989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological characteristics of the SARS-CoV-2 BA.2.86 variant.
    Tamura T; Mizuma K; Nasser H; Deguchi S; Padilla-Blanco M; Oda Y; Uriu K; Tolentino JEM; Tsujino S; Suzuki R; Kojima I; Nao N; Shimizu R; Wang L; Tsuda M; Jonathan M; Kosugi Y; Guo Z; Hinay AA; Putri O; Kim Y; Tanaka YL; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; ; Saito A; Ito J; Irie T; Tanaka S; Zahradnik J; Ikeda T; Takayama K; Matsuno K; Fukuhara T; Sato K
    Cell Host Microbe; 2024 Feb; 32(2):170-180.e12. PubMed ID: 38280382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3.
    Faraone JN; Qu P; Goodarzi N; Zheng YM; Carlin C; Saif LJ; Oltz EM; Xu K; Jones D; Gumina RJ; Liu SL
    Emerg Microbes Infect; 2023 Dec; 12(2):2270069. PubMed ID: 37819267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transmission and re-infection of Omicron variant XBB.1.5 in hamsters.
    Halfmann PJ; Uraki R; Kuroda M; Iwatsuki-Horimoto K; Yamayoshi S; Ito M; Kawaoka Y
    EBioMedicine; 2023 Jul; 93():104677. PubMed ID: 37352827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo.
    Uraki R; Kiso M; Iwatsuki-Horimoto K; Yamayoshi S; Ito M; Chiba S; Sakai-Tagawa Y; Imai M; Kashima Y; Koga M; Fuwa N; Okumura N; Hojo M; Iwamoto N; Kato H; Nakajima H; Ohmagari N; Yotsuyanagi H; Suzuki Y; Kawaoka Y
    Cell Rep; 2023 Dec; 42(12):113580. PubMed ID: 38103202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 Omicron XBB.1.5 and other mutants.
    Liu Z; Li J; Pei S; Lu Y; Li C; Zhu J; Chen R; Wang D; Sun J; Chen K
    Front Cell Infect Microbiol; 2023; 13():1297078. PubMed ID: 38156316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
    Wang Q; Iketani S; Li Z; Liu L; Guo Y; Huang Y; Bowen AD; Liu M; Wang M; Yu J; Valdez R; Lauring AS; Sheng Z; Wang HH; Gordon A; Liu L; Ho DD
    Cell; 2023 Jan; 186(2):279-286.e8. PubMed ID: 36580913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The return of the "Mistigri" (virus adaptative gain by gene loss) through the SARS-CoV-2 XBB.1.5 chimera that predominated in 2023.
    Colson P; Delerce J; Fantini J; Pontarotti P; La Scola B; Raoult D
    J Med Virol; 2023 Oct; 95(10):e29146. PubMed ID: 37800455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties - an alarming global threat of a surge in COVID-19 cases again?
    Chakraborty C; Bhattacharya M; Chopra H; Islam MA; Saikumar G; Dhama K
    Int J Surg; 2023 Apr; 109(4):1041-1043. PubMed ID: 36917125
    [No Abstract]   [Full Text] [Related]  

  • 20. Genomic epidemiology and evolutionary analysis during XBB.1.16-predominant periods of SARS-CoV-2 omicron variant in Bangkok, Thailand: December 2022-August 2023.
    Puenpa J; Chansaenroj J; Suwannakarn K; Poovorawan Y
    Sci Rep; 2024 Jan; 14(1):645. PubMed ID: 38182705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.